Skip to main content
NIH funding notice PAR-21-183

Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)

Closed on December 6, 2023.

Posted
March 23, 2021
Close date
December 6, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,172,914 in first-year total cost, median $794,714.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 JRB-A (16)]2
  2. Special Emphasis Panel[ZDA1 JRB-A (J6)]1

Most frequent institutions

  1. FRED HUTCHINSON CANCER CENTER1
  2. FRIENDS RESEARCH INSTITUTE, INC.1
  3. ROCHESTER INSTITUTE OF TECHNOLOGY1
Competing awards under PAR-21-183 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023Continuing Care App for Justice-Involved Individuals with Substance Use Disorders1UG3DA058305-01CARSWELL, STEVEN BERNARDGORDON, MICHAEL SCOTTFRIENDS RESEARCH INSTITUTE, INC., MD$573,506ZDA1
2022A Randomized Controlled Trial of A Digital, Self-Guided, Avatar Assisted- Cognitive Behavioral Therapy Platform to Treat Addiction: Digital RITch®CBT vs. Standard CBT1UG3DA057042-01EASTON, CAROLINE J.ROCHESTER INSTITUTE OF TECHNOLOGY, NY$804,694ZDA1
2022ACT on Vaping: Digital Therapeutic for Young Adult Vaping Cessation1UG3DA057032-01HEFFNER, JAIMEEFRED HUTCHINSON CANCER CENTER, WA$794,714ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-21-183: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional) | ScienceDex | ConductScience